Prostate-specific membrane antigen vaccines: Naked DNA and protein approaches

Clinical Prostate Cancer

Volumn 4, Issue 2, 2005, Pages 118-123

  Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Amino acids; Major histocompatibility complex; Prostate specific antigen; Vector

Indexed keywords

ANTIGEN; AUTOANTIGEN; BIOLOGICAL FACTOR; CANCER VACCINE; CARBOHYDRATE ANTIGEN; CYTOKINE; DNA VACCINE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; NAKED DNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN VACCINE; RECOMBINANT SOLUBLE PROSTATE SPECIFIC MEMBRANE ANTIGEN VACCINE; UNCLASSIFIED DRUG; VACCINE REPLICON PARTICLE PROSTATE SPECIFIC MEMBRANE PARTICLE;

ANTIGEN EXPRESSION; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; EFFECTOR CELL; GENE GUN; HUMAN; HUMORAL IMMUNITY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROSTATE CANCER; REPLICON; REVIEW; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 26944440031     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.020     Document Type: Article

References (35)

1. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998; 83:739-747.
2. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91:528-539.
3. Schulke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 2003; 100:12590-12595.
4. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3:81-85.
5. Chang SS, Reuter VE, Heston WD, et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 2001; 57:801-805.
6. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59:3192-3198.
7. Divgi CR, Bander NH, Scott AM, et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998; 4:2729-3239.
8. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170:1717-1721.
9. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000; 60:5237-5243.
10. Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22:2522-2531.
11. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170:S84-S88.
12. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40:125-129.
13. Gong MC, Latouche JB, Krause, et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1:123-127.
14. O'Keefe DS, Uchida A, Bacich, et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000; 45:149-157.
15. Gong MC, Chang SS, Watt F, et al. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol Urol 2000; 4:217-222.
16. Uchida A, O'Keefe DS, Bacich DJ, et al. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001; 58:132-139.
17. Mincheff M, Altankova I, Zoubak S, et al. In vivo transfection and/or cross-priming of dendritic cells following DNA and adenoviral immunizations for immunotherapy of cancer-changes in peripheral mononuclear subsets and intracellular IL-4 and IFN-gamma lymphokine profile. Crit Rev Oncol Hematol 2001; 39:125-132.
18. Lu J, Cellis E. Recognition of prostate tumor cell by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62:5807-5812.
19. Kuratsukuri K, Sone T, Wang CT, et al. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer 2002; 102:244-249.
20. Mincheff M, Zoubak S, Altankova I, et al. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther 2003; 10:907-917.
21. Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2000; 38:208-217.
22. Anilkumar G, Rajasekaran SA, Wang S, et al. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res 2003; 63:2645-2648.
23. Bacich DJ, Pinto JT, Tong WP, et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001; 12:117-123.
24. Yao R, Schneider E, Ryan TJ, et al. Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc Natl Acad Sci U S A 1996; 93:10134-10138.
25. Tasch J, Gong M, Sadelain M, et al. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol 2001; 21:249-261.
26. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58:4055-4060.
27. Slovin SF, Ragupathi G, Musselli C, et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol 2003; 21:4292-4298.
28. Slovin SF. Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity. Hematol Oncol Clin North Am 2001; 15:477-496
29. Slovin SF, Scher HI. Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center. Semin Oncol 1999; 26:448-454.
30. Wolchok JD, Gregor PD, Nordquist LT, et al. DNA vaccines: an active immunization strategy for prostate cancer. Semin Oncol 2003; 30:659-666.
31. Gregor PD, Wolchok JD, Ferrone CR, et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 2004; 22:1700-2708.
32. Fong L, Ruegg CL, Brickstedt D, et al. Induction of tissue specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. Cancer Res 1999; 59:3102-3198.
33. Gardner JP, Slovin SF, Morrissey DM, et al. Recombinant soluble prostate-specific membrane antigen (rsPSMA) vaccine: preliminary findings of a phase I safety/immunogenicity trial. Proc Amer Soc Clin Oncol 2004; 23:184 (Abstract #2584).
34. Gardner JP, Donovan GP, Schuelke N, et al. Active tumor immunotherapy using novel PSMA-based alphavirus and protein vaccines. Proc Amer Assoc Cancer Res 2003; 44:1088 (Abstract #4747).
35. Velders MP, McElhiney S, Cassetti MC, et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavurus 16 E7 RNA. Cancer Res 2001; 61:7861-7867.